177 related articles for article (PubMed ID: 31137920)
1. Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma.
Davidson M; Barber LJ; Woolston A; Cafferkey C; Mansukhani S; Griffiths B; Moorcraft SY; Rana I; Begum R; Assiotis I; Matthews N; Rao S; Watkins D; Chau I; Cunningham D; Starling N; Gerlinger M
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31137920
[TBL] [Abstract][Full Text] [Related]
2. ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA.
Huebner A; Black JRM; Sarno F; Pazo R; Juez I; Medina L; Garcia-Carbonero R; Guillén C; Feliú J; Alonso C; Arenillas C; Moreno-Cárdenas AB; Verdaguer H; Macarulla T; Hidalgo M; McGranahan N; Toledo RA
Genome Med; 2023 Apr; 15(1):27. PubMed ID: 37081523
[TBL] [Abstract][Full Text] [Related]
3. Low-cost and clinically applicable copy number profiling using repeat DNA.
Abujudeh S; Zeki SS; van Lanschot MCJ; Pusung M; Weaver JMJ; Li X; Noorani A; Metz AJ; Bornschein J; Bower L; Miremadi A; Fitzgerald RC; Morrissey ER; Lynch AG
BMC Genomics; 2022 Aug; 23(1):599. PubMed ID: 35978291
[TBL] [Abstract][Full Text] [Related]
4. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG
Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract][Full Text] [Related]
6. Unbiased Detection of Somatic Copy Number Aberrations in cfDNA of Lung Cancer Cases and High-Risk Controls with Low Coverage Whole Genome Sequencing.
Taylor F; Bradford J; Woll PJ; Teare D; Cox A
Adv Exp Med Biol; 2016; 924():29-32. PubMed ID: 27753014
[TBL] [Abstract][Full Text] [Related]
7. Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients.
Liao H; Zhang J; Zheng T; Liu X; Zhong J; Shao B; Dong X; Wang X; Du P; King BL; Jia S; Yu J; Li H
J Transl Med; 2022 May; 20(1):211. PubMed ID: 35562750
[TBL] [Abstract][Full Text] [Related]
8. Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma.
Beasley A; Isaacs T; Khattak MA; Freeman JB; Allcock R; Chen FK; Pereira MR; Yau K; Bentel J; Vermeulen T; Calapre L; Millward M; Ziman MR; Gray ES
JCO Precis Oncol; 2018; 2():. PubMed ID: 32913999
[TBL] [Abstract][Full Text] [Related]
9. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.
Stover DG; Parsons HA; Ha G; Freeman SS; Barry WT; Guo H; Choudhury AD; Gydush G; Reed SC; Rhoades J; Rotem D; Hughes ME; Dillon DA; Partridge AH; Wagle N; Krop IE; Getz G; Golub TR; Love JC; Winer EP; Tolaney SM; Lin NU; Adalsteinsson VA
J Clin Oncol; 2018 Feb; 36(6):543-553. PubMed ID: 29298117
[TBL] [Abstract][Full Text] [Related]
10. Current Applications and Challenges of Next-Generation Sequencing in Plasma Circulating Tumour DNA of Ovarian Cancer.
Roque R; Ribeiro IP; Figueiredo-Dias M; Gourley C; Carreira IM
Biology (Basel); 2024 Jan; 13(2):. PubMed ID: 38392306
[TBL] [Abstract][Full Text] [Related]
11. Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content.
Ganesamoorthy D; Robertson AJ; Chen W; Hall MB; Cao MD; Ferguson K; Lakhani SR; Nones K; Simpson PT; Coin LJM
BMC Cancer; 2022 Jan; 22(1):85. PubMed ID: 35057759
[TBL] [Abstract][Full Text] [Related]
12. Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells.
Court CM; Hou S; Liu L; Winograd P; DiPardo BJ; Liu SX; Chen PJ; Zhu Y; Smalley M; Zhang R; Sadeghi S; Finn RS; Kaldas FM; Busuttil RW; Zhou XJ; Tseng HR; Tomlinson JS; Graeber TG; Agopian VG
NPJ Precis Oncol; 2020; 4():16. PubMed ID: 32637655
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Circulating Tumour DNA and Extracellular Vesicle DNA by Low-Pass Whole-Genome Sequencing Reveals Molecular Drivers of Disease in a Breast Cancer Patient.
Ruhen O; Mirzai B; Clark ME; Nguyen B; Salomon C; Erber W; Meehan K
Biomedicines; 2020 Dec; 9(1):. PubMed ID: 33375577
[TBL] [Abstract][Full Text] [Related]
14. Pervasive chromosomal instability and karyotype order in tumour evolution.
Watkins TBK; Lim EL; Petkovic M; Elizalde S; Birkbak NJ; Wilson GA; Moore DA; Grönroos E; Rowan A; Dewhurst SM; Demeulemeester J; Dentro SC; Horswell S; Au L; Haase K; Escudero M; Rosenthal R; Bakir MA; Xu H; Litchfield K; Lu WT; Mourikis TP; Dietzen M; Spain L; Cresswell GD; Biswas D; Lamy P; Nordentoft I; Harbst K; Castro-Giner F; Yates LR; Caramia F; Jaulin F; Vicier C; Tomlinson IPM; Brastianos PK; Cho RJ; Bastian BC; Dyrskjøt L; Jönsson GB; Savas P; Loi S; Campbell PJ; Andre F; Luscombe NM; Steeghs N; Tjan-Heijnen VCG; Szallasi Z; Turajlic S; Jamal-Hanjani M; Van Loo P; Bakhoum SF; Schwarz RF; McGranahan N; Swanton C
Nature; 2020 Nov; 587(7832):126-132. PubMed ID: 32879494
[TBL] [Abstract][Full Text] [Related]
15. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
[TBL] [Abstract][Full Text] [Related]
16. Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival.
Chen Y; Sadasivan SM; She R; Datta I; Taneja K; Chitale D; Gupta N; Davis MB; Newman LA; Rogers CG; Paris PL; Li J; Rybicki BA; Levin AM
BMC Med Genomics; 2020 Aug; 13(1):116. PubMed ID: 32819446
[TBL] [Abstract][Full Text] [Related]
17. Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients.
Buder A; Heitzer E; Waldispühl-Geigl J; Weber S; Moser T; Hochmair MJ; Hackner K; Errhalt P; Setinek U; Filipits M
Biomolecules; 2021 Apr; 11(5):. PubMed ID: 33919291
[TBL] [Abstract][Full Text] [Related]
18. ctDNA as a biomarker of progression in oesophageal adenocarcinoma.
Bonazzi VF; Aoude LG; Brosda S; Lonie JM; Patel K; Bradford JJ; Koufariotis LT; Wood S; Smithers BM; Waddell N; Barbour AP
ESMO Open; 2022 Jun; 7(3):100452. PubMed ID: 35798469
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA-based copy-number profiles enable monitoring treatment effects during therapy in high-grade serous carcinoma.
Nguyen MTN; Rajavuori A; Huhtinen K; Hietanen S; Hynninen J; Oikkonen J; Hautaniemi S
Biomed Pharmacother; 2023 Dec; 168():115630. PubMed ID: 37806091
[TBL] [Abstract][Full Text] [Related]
20. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
Ricciuti B; Jones G; Severgnini M; Alessi JV; Recondo G; Lawrence M; Forshew T; Lydon C; Nishino M; Cheng M; Awad M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
